Dendrimer Grafted Albumin Nanoparticles for the Treatment of Post Cerebral Stroke Damages: A Proof of Concept Study

Publication date: Available online 3 September 2019Source: Colloids and Surfaces B: BiointerfacesAuthor(s): Deepak Pradhan, Vishakha Tambe, Nidhi Raval, Piyush Gondalia, Pallab Bhattacharya, Kiran Kalia, Rakesh K. TekadeAbstractStroke is the second largest disease of mortality. The biggest hurdle in designing effective brain drug delivery systems is offered by the blood-brain barrier (BBB), which is highly impermeable to many drugs. Albumin nanoparticles (NP) have gained attention due to their multiple ligand binding sites and long circulatory half-life. Citicoline (CIT) is reported to enhance the acetylcholine secretion in the brain and also helps in membrane repair and regeneration. However, the poor BBB permeation of CIT results in lower levels of CIT in the brain. This demands the development of a suitable delivery platform to completely realize the therapeutic benefit of CIT in stroke therapy. This investigation reports the synthesis and characterization of second generation (2.0 G) dendrimer Amplified Albumin (dAA) biopolymer by FTIR, MALDI-TOF, and surface charge (mV). Further, the synthesized biopolymer has been utilized to develop a CIT nanoformulation using a commercially translatable one-pot process. Release of CIT from biopolymer was performed within an acetate buffer at pH 5 and Phosphate buffer at pH 7.4. Further, we investigated the ability of biopolymer to permeate BBB by in vitro permeability assay in bEnd.3 cells. MTT assay of CIT-dAA-NP, CIT-ANP, and 2.0â...
Source: Colloids and Surfaces B: Biointerfaces - Category: Biochemistry Source Type: research